JP5769308B2 - 貧血又はｈ．ピロリ感染に用いる単（鉄ヒドロキシピロン）及び組み合わせ（鉄ヒドロキシピロン及び胃腸炎抑止剤）組成物 - Google Patents

貧血又はｈ．ピロリ感染に用いる単（鉄ヒドロキシピロン）及び組み合わせ（鉄ヒドロキシピロン及び胃腸炎抑止剤）組成物 Download PDF

Info

Publication number
JP5769308B2
JP5769308B2 JP2011509003A JP2011509003A JP5769308B2 JP 5769308 B2 JP5769308 B2 JP 5769308B2 JP 2011509003 A JP2011509003 A JP 2011509003A JP 2011509003 A JP2011509003 A JP 2011509003A JP 5769308 B2 JP5769308 B2 JP 5769308B2
Authority
JP
Japan
Prior art keywords
iron
hydroxypyrone
cobalt
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011509003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520855A5 (https=
JP2011520855A (ja
Inventor
アーサー ストッカム、マイケル
アーサー ストッカム、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iron Therapeutics Holdings AG
Original Assignee
Iron Therapeutics Holdings AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iron Therapeutics Holdings AG filed Critical Iron Therapeutics Holdings AG
Publication of JP2011520855A publication Critical patent/JP2011520855A/ja
Publication of JP2011520855A5 publication Critical patent/JP2011520855A5/ja
Application granted granted Critical
Publication of JP5769308B2 publication Critical patent/JP5769308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011509003A 2008-05-15 2009-05-14 貧血又はｈ．ピロリ感染に用いる単（鉄ヒドロキシピロン）及び組み合わせ（鉄ヒドロキシピロン及び胃腸炎抑止剤）組成物 Active JP5769308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0808835.3 2008-05-15
GBGB0808835.3A GB0808835D0 (en) 2008-05-15 2008-05-15 Therapeutic compositions
PCT/GB2009/001231 WO2009138761A1 (en) 2008-05-15 2009-05-14 Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014237229A Division JP2015083572A (ja) 2008-05-15 2014-11-24 鉄ヒドロキシピロンを含む薬剤組成物

Publications (3)

Publication Number Publication Date
JP2011520855A JP2011520855A (ja) 2011-07-21
JP2011520855A5 JP2011520855A5 (https=) 2012-06-28
JP5769308B2 true JP5769308B2 (ja) 2015-08-26

Family

ID=39571409

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011509003A Active JP5769308B2 (ja) 2008-05-15 2009-05-14 貧血又はｈ．ピロリ感染に用いる単（鉄ヒドロキシピロン）及び組み合わせ（鉄ヒドロキシピロン及び胃腸炎抑止剤）組成物
JP2014237229A Pending JP2015083572A (ja) 2008-05-15 2014-11-24 鉄ヒドロキシピロンを含む薬剤組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014237229A Pending JP2015083572A (ja) 2008-05-15 2014-11-24 鉄ヒドロキシピロンを含む薬剤組成物

Country Status (9)

Country Link
US (2) US9248148B2 (https=)
EP (1) EP2303289A1 (https=)
JP (2) JP5769308B2 (https=)
CN (1) CN102099042B (https=)
AU (1) AU2009247762B2 (https=)
CA (1) CA2724172C (https=)
GB (1) GB0808835D0 (https=)
SG (1) SG182137A1 (https=)
WO (1) WO2009138761A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829272A (zh) 2009-12-22 2015-08-12 拉尔科营养品有限公司 有机螯合的矿物组合物及其制备方法
GB201101370D0 (en) 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
CN104640825A (zh) * 2012-07-05 2015-05-20 拉尔科营养品有限公司(美国) 利用矿物质化合物的农业组合物和应用
US10179120B2 (en) * 2014-01-06 2019-01-15 Iron Therapeutics Holdings Ag Dosage regimen of ferric trimaltol
GB201404390D0 (en) * 2014-03-12 2014-04-23 Iron Therapeutics Holdings Ag Composition
UA117786C2 (uk) 2014-04-17 2018-09-25 Ралко Нутрітіон, Інк. Сільськогосподарські композиції та застосування з використанням мінеральних сполук
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
WO2016112381A1 (en) 2015-01-09 2016-07-14 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
JP2017032550A (ja) * 2015-07-30 2017-02-09 大塚製薬株式会社 胃粘膜萎縮の有無を判定する方法
CA3019478C (en) * 2016-03-31 2024-02-13 United Kingdom Research And Innovation Ferric maltol compositions for use in the treatment or prevention of cancer and tumours
GB2553099A (en) * 2016-08-19 2018-02-28 Shield Tx Uk Ltd Use
IT201700021676A1 (it) * 2017-02-28 2018-08-28 Carlo Angelo Ghisalberti Composizioni e sistemi di estrazione del ferro non-eme dalla dieta per uso nell’anemia sideropenica e carenze marziali

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
US5177068A (en) 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
AU6010696A (en) 1995-06-10 1997-01-09 Vitra Pharmaceuticals Ltd Iron compounds, compositions, methods of making the same and uses thereof
GB9621273D0 (en) * 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB0012487D0 (en) 2000-05-24 2000-07-12 Pfylori Limited Use of metal compounds to treat gastrointestinal infections
US7135196B2 (en) * 2000-09-19 2006-11-14 Vitra Pharmaceuticals Limited Iron compositions
GB0211500D0 (en) 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
EP1686982A4 (en) 2003-11-19 2007-03-21 Vecta Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI USING COMPOUNDS CONTAINING ENDOPEROXIDE BRIDGE
EP1973549B1 (en) * 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
WO2007108712A1 (en) 2006-03-17 2007-09-27 Tatyana Vyacheslavovna Popkova Kit and method for treating or preventing anemia caused by iron deficiency
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption

Also Published As

Publication number Publication date
WO2009138761A1 (en) 2009-11-19
GB0808835D0 (en) 2008-06-18
US20110177172A1 (en) 2011-07-21
US9248148B2 (en) 2016-02-02
SG182137A1 (en) 2012-07-30
AU2009247762B2 (en) 2014-08-14
JP2011520855A (ja) 2011-07-21
CN102099042A (zh) 2011-06-15
CA2724172C (en) 2017-07-25
CN102099042B (zh) 2014-08-13
AU2009247762A1 (en) 2009-11-19
CA2724172A1 (en) 2009-11-19
US20160120902A1 (en) 2016-05-05
EP2303289A1 (en) 2011-04-06
JP2015083572A (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
JP5769308B2 (ja) 貧血又はｈ．ピロリ感染に用いる単（鉄ヒドロキシピロン）及び組み合わせ（鉄ヒドロキシピロン及び胃腸炎抑止剤）組成物
EP0942720B1 (en) Use of metal complexes to treat gastrointestinal infections
JP7150976B2 (ja) 抗血小板剤と胃酸分泌阻害剤を含む医薬組成物
HRP930755A2 (en) Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
US20080233206A1 (en) Compositions and methods for anti-inflammatory treatments
EP1318804B1 (en) Iron compositions
US6426369B1 (en) Oxethazaine as antimicrobial agent
AU776732B2 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines C
AU2008352018A1 (en) Methods to inhibit tumor cell growth by using proton pump inhibitors
JPH0539219A (ja) 胸やけ、胃痛または胃酸過多に関連した胃の不調の発泡性ｈ２ブロツカー製剤による治療
HK1156552A (en) Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and gi inflammation inhibiting agents) compositions for anaemia or h. pylori infections
HK1156552B (en) Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and gi inflammation inhibiting agents) compositions for anaemia or h. pylori infections
KR101153571B1 (ko) 테나토프라졸 및 히스타민 ｈ2-수용체 길항제를 배합한제약 조성물
Eddlestone Drug Therapies Used in Gastrointestinal
Lambert Effect of Antiulcer drugs on Helicobacter pylori
JP2000080031A (ja) 抗菌剤
US20020115636A1 (en) Composition for treating equine gastric ulcers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150619

R150 Certificate of patent or registration of utility model

Ref document number: 5769308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250